As the HLH Imaging Group prepares to attend RSNA 2026, its focus will be on how to deliver population screening safely, consistently and at scale.
Lung cancer screening is already demonstrating what this challenge looks like in practice, the company says. High volume screening programmes require more than additional reporting capacity. They depend on standardised reporting, robust clinical governance, effective use of AI, interoperable IT systems and workflows capable of supporting large numbers of patients across multiple organisations.
HLH says it has gained significant experience in this area through its work supporting NHS lung cancer screening programmes across England. “That experience has reinforced the importance of designing infrastructure around the whole screening pathway, rather than viewing radiology reporting as an isolated component,” the company says.
“Increasingly, the same discussion is extending into other disease areas. Prostate screening is of particular interest, with MRI, structured reporting and AI-assisted workflows creating the potential for scalable, high quality pathways as evidence and screening models continue to develop.”
The company adds that RSNA will provide an opportunity to explore how technology, clinical expertise and operational design can come together to support the next generation of population imaging programmes.
Commercial and operations director Saul Charalambos and director of IT and clinical systems David Douglas will be at the congress to meet with technology partners, clinical teams and healthcare organisations.
Schedule a meeting at RSNA by emailing: info@thehlhgroup.com.
Picture: HLH Imaging Group COO Dr Graham Robinson, commercial and operations director Saul Charalambos and director of IT and clinical systems David Douglas.
Visit our dedicated RSNA conference page to find out more.
